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Abstract
Background: Deep brain stimulation (DBS) is an increasingly utilized therapeutic modality for the management of medication refractory essential tremor (ET).
The aim of this study was to determine whether DBS allowed for anti-tremor medication reduction within the year after the procedure was performed.
Methods: We conducted a retrospective chart review and telephone interviews on 34 consecutive patients who had been diagnosed with ET, and who had
undergone unilateral DBS surgery.
Results: Of the 34 patients in our cohort, 31 patients (91%) completely stopped all anti-tremor medications either before surgery (21 patients, 62%) or in the year
following DBS surgery (10 patients, 29%). Patients who discontinued tremor medications before DBS surgery did so because their tremors either became refractory
to anti-tremor medication, or they developed adverse events to tremor medications. Patients who stopped tremor medications after DBS surgery did so due to
sufficient tremor control. Only three patients (9%) who were taking tremor medications at the time of surgery continued the use of a beta-blocker post-operatively
for the purpose of hypertension management in all cases.
Discussion: The data from this study indicate that medication cessation is common following unilateral DBS for ET.
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Introduction
Essential Tremor (ET) is a progressive, neurological disorder that is
characterized by postural, intention, and kinetic tremor.1–3 It is
estimated that more than 10 million people in the United States suffer
from ET.4–6 Medication therapy is often used to control and mitigate
symptoms, although medications may not prove efficacious in many
cases.7,8
Deep brain stimulation (DBS) is an increasingly and commonly utilized
therapeutic modality that is thought to work by disrupting a cerebello-
thalamic-cortical loop that has been implicated in the genesis of the
abnormal oscillation.9–11 DBS has a higher magnitude of effect in treating
ET than medications, although it may be associated with infrequent but
more serious side effects. The primary aim of this study was to evaluate
whether anti-tremor medications could be reduced or discontinued in the
year following DBS surgery for the management of ET.
Methods
Consecutive subjects from the University of South Florida (USF)
Parkinson’s Disease and Movement Disorders Center were identified
using an Institutional Review Board-approved protocol. A query of the
center’s electronic database was performed to identify patients with a
diagnosis of ET. Charts were individually reviewed to assess eligibility
criteria, which included 1) a unilateral thalamic DBS device implanted
between October 2000 through October 2010 (Medtronic Activa
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Therapy, Minneapolis, Minnesota); 2) a diagnosis of ET made by a
movement disorders specialist (T.A.Z.); 3) the indication for DBS
surgery to alleviate tremor in the dominant hand, or, alternatively, to
alleviate tremor in the more affected hand; 4) the following of each
patient at our center for programming/medication management.
Each patient’s electronic chart was reviewed for specific variables:
anti-tremor medications taken 1 year before (Table 1) and 1 year after
the DBS surgery, date of DBS surgery, current age, age at time of
surgery, disease duration at time of surgery, sex, family history,
confirmation of unilateral implantation, and severity of tremor.
Subjective variables such as improvement in sleep patterns and overall
cognition were also asked during patient interview. Subjects were then
classified into two categories based upon the length of time diagnosed
with ET: long disease duration (LDD: >10 years) and short disease
duration (SDD: ,10 years). Within each category, patients were then
further classified into those who 1) were refractory to anti-tremor
medications (patients whose tremor became resistant or unresponsive
to such medications even at maximally tolerated doses) and ceased
their use prior to surgery, 2) experienced adverse events from taking
anti-tremor medications and who also ceased their use prior to surgery,
and 3) had derived benefit from anti-tremor medications and therefore
continued to take them at the time of their surgery.
Results
Forty-four patients were identified in the initial chart review and 10
of these patients (23%) were excluded from the study because they
were either not followed at our center for DBS programming/
medication management (seven patients, 16%), or they were deceased
(three patients, 7%). Data from 34 patients was reviewed. The mean
age of patients in the study was 76 ¡ 16.2 years (range 35–89 years)
and 23 patients (68%) were male. The mean age at the time of DBS
surgery was 70¡ 18.1 years (range 35–89 years) and the mean age at
time of diagnosis was 49 ¡ 22.7 years (range 10–80 years). Twelve
patients (35%) reported a family history of tremor. Thirty-one of the
34 patients (91%) received left-sided ventral intermediate nucleus
(VIM) DBS implantation for tremor management; three left-handed
patients were implanted on the right side (9%). All patients had tremor
that was regarded by their evaluating physicians as ‘‘severe.’’ Twenty-
three patients (68%) had been diagnosed with ET for a period of 10
years or more (LDD group, mean 21 years) prior to their date of DBS
surgery (range 10–51 years). All patients had previously experienced
efficacy from medications, however medication benefit waned.
Of the 34 patients in the cohort, 31 patients (91%) completely
stopped all anti-tremor medications before or after surgery (Figure 1).
Twenty-one (62%) of 31 patients stopped medication before surgery,
either because their tremors became refractory to anti-tremor
medication or because they developed adverse events to tremor
medications. Ten (29%) of 31 patients stopped medications in the year
after DBS due to sufficient tremor control. Three patients (9%) who
were taking tremor medications at the time of surgery continued the
use of a beta-blocker post-operatively for the purpose of hypertension
management.
When evaluating the cohort with respect to duration of ET, 17 of 23
patients (74%) with LDD ET stopped anti-tremor medication(s)
(primidone, propranolol, and topiramate) at least 1 year prior to DBS
surgery. Of these, 13 patients stopped anti-tremor medications due to
lack of efficacy, while four patients discontinued anti-tremor medica-
tions due to adverse events. Of the 11 patients who had a diagnosis of
ET for a period of less than 10 years (SDD group), four of them (36%)
stopped anti-tremor medications at least 1 year prior to DBS due to
side effects of anti-tremor medications during upward titration of
dosage(s).
Thirty patients (88%) reported subjective improvement in sleep
patterns throughout the night and 29 patients (85%) reported an
overall improvement in their general cognitive state when combining
DBS with the discontinuation of anti-tremor medications. Further
details regarding discontinuation of anti-tremor medications before
and after DBS surgery are reported in Figure 1.
Discussion
DBS is now widely utilized for the treatment of many medication-
refractory movement disorders. The primary goal of the study was to
evaluate how DBS for ET would impact use of anti-tremor
medications following DBS. Our findings indicate that approximately
three-quarters of ET patients who underwent DBS and who had not
previously terminated anti-tremor medications eventually stopped
taking anti-tremor medications within the year following DBS surgery.
The main reason for termination of previous anti-tremor pharma-
cotherapy post-operatively was successful reduction or complete
abolition of tremor from DBS surgery. The study also found that















Short Disease Duration1 2 2 0 5 0 2
Long Disease Duration2 7 4 0 10 2 0
1Number of patients taking medication prior to DBS surgery (n511).
2Number of patients taking medication prior to DBS surgery (n523).
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Figure 1. Quantitative breakdown of tremor medication usage among patients. DBS, deep brain stimulation; LDD, long disease duration; SDD, short disease duration.
Table 2. Pub-Med Literature Review Documenting Various Studies Relating Essential Tremor (ET) and Deep Brain Stimulation (DBS).
Author Number of
Patients (n)




Barbe, et al.32 23 2010 VIM Not detailed ADLs improved significantly and optimal stimu-
lation parameters in ET patients led to initial
short-term improvement that adjusted over
time.
Flora, et al.33 430 2010 VIM Not detailed ‘‘…[medication] treatments have limited suc-
cess and can become ineffective over time. For
medication-refractory patients, alternative
treatment is limited to thalamotomy or DBS.’’
Blomstedt, et al.34 21 2010 Posterior
subthalamic
area
Not detailed ADLs improved by 66% and stimulation at this
target resulted in significant tremor reduction.
Lyons, et al.23 Not
indicated
2003 VIM Not detailed Reports that current tremor medications are
effective in 50% of patients. Also reports that
surgical options for tremor are effective in 90%
of patients.
Fields, et al.35 40 2003 VIM Not detailed DBS improved quality of life outcomes, cogni-
tion, and mood. Anxiety was also improved.
Perlmutter, et al.36 Not
indicated
2002 VIM Not detailed Increased blood flow shows that DBS ‘‘stimu-
lates and does not inactivate projection neurons
in VIM thalamus.’’
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Koller, et al.37 49 2001 VIM Not detailed Unilateral DBS of the thalamus is efficacious for
a portion of ET patients, however this is
compromised by device complications.
Pahwa et al.38 35 2001 VIM Not detailed Thalamotomy has a higher rate of complications
and DBS should be chosen over thalamotomy
when considering surgical treatment.
Koller, et al.39 Not
indicated
2000 VIM Not detailed DBS is highly effective for the treatment of
tremor and is preferred to thalamotomy.
Pahwa, et al.40 Not
indicated
2000 VIM Not detailed Thalamotomy and DBS are stereotactic proce-
dures that aid in the treatment of ET. While
both are associated with morbidities, medica-
tion-refractory patients can be candidates for
both Not Mentioned procedures.
Tro¨ster et al.41 40 1999 VIM Not detailed Unilateral DBS of the thalamus for ET is
considered safe and associated with anxiety and
quality of life improvements.
Pahwa, et al.42 9 1999 VIM Not detailed Bilateral DBS is effective in improving tremor
and disability in patients with ET, however,
dysarthria can be an adverse effect of the
stimulation.
Koller, et al.43 29
(Diagnosed
with ET)
1997 VIM Not detailed High-frequency stimulation for ET and parkin-
sonian tremor patients is well tolerated, highly
effective, and had only mild adverse effects.
Hubble, et al.44 10 1996 VIM Not detailed DBS is considered to be safe and effective in its
reduction of tremor and disability in patients
with ET.
Lyons, et al.45 Not
indicated
2008 VIM Not detailed DBS is effective in treating medication-refrac-
tory and disabling ET. Surgical complications are
typically uncommon.
Pahwa, et al.46 26
(Diagnosed
with ET)
2006 VIM Not detailed DBS for long-term management of ET is safe
and considered to be effective. Bilateral
stimulation is associated with dysarthria
incoordination.
Graff-Radford, et al.47 31 2010 VIM Not detailed Tremor rating scale subscale scores improved
for all unilateral and bilateral VIM DBS patients.
Subscale scores for visual analog mood scale
varied for unilateral and bilateral DBS patients.
Ondo, et al.48 73 2001 VIM Not detailed Tremor on contralateral side ‘‘improved sig-
nificantly and robustly in PD and ET’’ after VIM
DBS. Tremor was not worsened on ipsilateral
side, but rather mildly improved in ET patients.
Abbreviations: ADLs, activities of daily living; PD, Parkinson’s disease; VIM, ventral intermediate nucleus.
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anti-tremor medications are less effective in long duration ET (>10
years) than in short duration ET (,10 years).
Pharmacological effects in patients with ET have been previously
characterized by several studies.8,13–22 Lyons et al.24 found that anti-
tremor medications were limited in their ability to control tremor, and
only effectively treated tremor in half of ET patients.12,23, In contrast,
DBS has been reported to result in a 60–90% reduction in tremor
amplitude.25 Side effects from DBS, however, may be more serious.
Table 2 summarizes major studies of DBS and/or pharmacotherapy
for ET.
Propranolol and primidone have been identified as the two main
pharmacological therapies for treatment of ET and authors have
generally reported that their use results in a reduction of tremor by half
in 50% of patients.23 Propranolol, despite being used solely for tremor,
is also an effective therapy for the treatment of hypertension and other
cardiac issues, however, depression, low blood pressure, and other
cognitive issues have been associated with its use.14,26,27 Three patients
in our cohort who discontinued anti-tremor medications within 1 year
following DBS surgery continued on a beta-blocker with the cited
indication being hypertension (two patients from the LDD group and
one patient from the SDD group). An important limitation to the
current study was that propranolol may have provided a symptomatic
effect in these patients and inflated their improvement scores following
DBS.28 Additionally, small sample size, retrospective nature of the
study, and data obtained only by a telephone interview and patient
chart review (not in a clinical setting) were other limitations in our
study.
There are economic and symptomatic benefits for medication
discontinuation, particularly primidone, which has been reported to be
associated with lethargy and cognitive issues in addition to difficulty
with tolerance and upward titration.29–31 Thus, medication disconti-
nuation post-DBS may result in improved cognition, reduction of side
effects, and improved sleep patterns. However, despite these benefits,
practitioners should be aware that medication reduction could have a
symptomatic price, particularly on the contralateral extremity in the
case of unilateral VIM DBS. Although our study did not specifically
address bilateral VIM DBS, which is associated with more side effects
(e.g. speech, gait), it is interesting that medication reduction occurred
at such a high prevalence.
Our cohort found that discontinuation of medications for ET
patients post-DBS was common. As neuromodulation therapy evolves
for ET, it will be the responsibility of the practitioner to carefully
choose the proper treatment for each patient, whether pharmacolo-
gical or surgical. Future research studies should include long-term
studies on the use of medication therapy following DBS surgery,
including patients with bilateral stimulation. Recognizing that each
patient is unique will be a critical step in optimizing outcomes.
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